Welcome to our dedicated page for MIMI news (Ticker: MIMI), a resource for investors and traders seeking the latest updates and insights on MIMI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MIMI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MIMI's position in the market.
Mint Incorporation (Nasdaq: MIMI), a Hong Kong-based interior design and fit out works provider, has announced the pricing of its initial public offering of 1,750,000 Class A ordinary shares at $4.00 per share. Trading is expected to begin on Nasdaq Capital Market on January 10, 2025, under the symbol 'MIMI'.
The company expects to raise $7 million in gross proceeds, with anticipated net proceeds of $4.80 million after deducting underwriting discounts and expenses. Underwriters have a 45-day option to purchase up to additional 262,500 shares. The funds will be used for expanding business operations in the USA and UK, potential strategic investments, IT services upgrade, and working capital.
Benjamin Securities is acting as the representative underwriter, with Prime Number Capital as co-underwriter. The offering is being conducted on a firm commitment basis and is expected to close on January 13, 2025.
Mimi's Rock Corp. (TSXV:MIMI) and Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) have launched Dr. Tobias Beta Blend, a dietary supplement aimed at enhancing immune support and promoting skin and eye health. Available exclusively on Amazon and DrTobias.com, the product leverages Avivagen’s proprietary OxC-beta™ technology. Retailing at USD $29.97, this collaboration is expected to meet strong consumer demand, particularly in light of heightened awareness of immune health due to COVID-19.
FAQ
What is the current stock price of MIMI (MIMI)?
